Rhythm control in atrial fibrillation

The Lancet

Volumn 388, Issue 10046, 2016, Pages 829-840

  Piccini, Jonathan P ^a   Fauchier, Laurent ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ATRIAL FIBRILLATION; CARDIOVERSION; CATHETER ABLATION; CATHETER COMPLICATION; CHRONIC KIDNEY DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SINUS RHYTHM; SURGICAL APPROACH; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT INDICATION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEART RATE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; STROKE; TIME FACTOR;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; HEART FAILURE; HEART RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; STROKE; THROMBOEMBOLISM; TIME FACTORS; VITAMIN K;

EID: 84988489846     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31277-6     Document Type: Review

References (94)

1. 1 Chugh, SS, Havmoeller, R, Narayanan, K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
2. 2 The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 31 (2010), 2369–2429.
3. 3 Camm, AJ, Lip, GY, De Caterina, R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14 (2012), 1385–1413.
4. 4 January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–76.
5. 5 Nuotio, I, Hartikainen, JE, Gronberg, T, Biancari, F, Airaksinen, KE, Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA 312 (2014), 647–649.
6. 6 Klein, AL, Grimm, RA, Murray, RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (2001), 1411–1420.
7. 7 Gallagher, MM, Hennessy, BJ, Edvardsson, N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 40 (2002), 926–933.
8. 8 Manios, EG, Mavrakis, HE, Kanoupakis, EM, et al. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther 17 (2003), 31–39.
9. 9 Bianconi, L, Mennuni, M, Lukic, V, Castro, A, Chieffi, M, Santini, M, Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 28 (1996), 700–706.
10. 10 Kirchhof, P, Eckardt, L, Loh, P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360 (2002), 1275–1279.
11. 11 Kondili, A, Kastrati, A, Popa, Y, Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. Wien Klin Wochenschr, 1990, B510–B513.
12. 12 Martínez-Marcos, FJ, García-Garmendia, JL, Ortega-Carpio, A, Fernández-Gómez, JM, Santos, JM, Camacho, C, Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 86 (2000), 950–953.
13. 13 Reisinger, J, Gatterer, E, Lang, W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 25 (2004), 1318–1324.
14. 14 Corvert—butilide fumarate injection solution. Package insert. http://labeling.pfizer.com/showlabeling.aspx?id=673 (accessed July 8, 2016).
15. 15 Roy, D, Pratt, CM, Torp-Pedersen, C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117 (2008), 1518–1525.
16. 16 Pratt, CM, Roy, D, Torp-Pedersen, C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 106 (2010), 1277–1283.
17. 17 Letelier, LM, Udol, K, Ena, J, Weaver, B, Guyatt, GH, Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 163 (2003), 777–785.
18. 18 Alboni, P, Botto, GL, Baldi, N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 351 (2004), 2384–2391.
19. 19 Fuster, V, Ryden, LE, Cannom, DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 48 (2006), 854–906.
20. 20 Freemantle, N, Lafuente-Lafuente, C, Mitchell, S, Eckert, L, Reynolds, M, Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13 (2011), 329–345.
21. 21 Pritchett, EL, Page, RL, Carlson, M, Undesser, K, Fava, G, Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 92 (2003), 941–946.
22. 22 Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321 (1989), 406–412.
23. 23 Wolbrette, DL, Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 91 (2003), 39D–44D.
24. 24 Singh, BN, Connolly, SJ, Crijns, HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357 (2007), 987–999.
25. 25 Hohnloser, SH, Crijns, HJ, van Eickels, M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360 (2009), 668–678.
26. 26 Piccini, JP, Hasselblad, V, Peterson, ED, Washam, JB, Califf, RM, Kong, DF, Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 54 (2009), 1089–1095.
27. 27 Connolly, SJ, Camm, AJ, Halperin, JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365 (2011), 2268–2276.
28. 28 Kober, L, Torp-Pedersen, C, McMurray, JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008), 2678–2687.
29. 29 Di Biase, L, Mohanty, P, Mohanty, S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133 (2016), 1637–1644.
30. 30 Piccini, JP, Pritchett, EL, Davison, BA, et al. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Heart Rhythm, 2016, 10.1016/j.hrthm.2016.04.012 published online April 19.
31. 31 Van Wagoner, DR, Piccini, JP, Albert, CM, et al. Progress toward the prevention and treatment of atrial fibrillation: a summary of the Heart Rhythm Society research forum on the treatment and prevention of atrial fibrillation, Washington, DC, December 9–10, 2013. Heart Rhythm 12 (2015), e5–29.
32. 32 Sidorova, TN, Yermalitskaya, LV, Mace, LC, et al. Reactive gamma-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells. J Mol Cell Cardiol 79 (2015), 295–302.
33. 33 Darbar, D, Motsinger, AA, Ritchie, MD, Gainer, JV, Roden, DM, Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm 4 (2007), 743–749.
34. 34 Dimitri, H, Ng, M, Brooks, AG, et al. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm 9 (2012), 321–327.
35. 35 Naruse, Y, Tada, H, Satoh, M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 10 (2013), 331–337.
36. 36 Pathak, RK, Middeldorp, ME, Meredith, M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65 (2015), 2159–2169.
37. 37 Pathak, RK, Middeldorp, ME, Lau, DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64 (2014), 2222–2231.
38. 38 Hess, PL, Kim, S, Piccini, JP, et al. Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med 126 (2013), 625–632.
39. 39 Healey, JS, Baranchuk, A, Crystal, E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005), 1832–1839.
40. 40 Patti, G, Chello, M, Candura, D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006), 1455–1461.
41. 41 Zheng, Z, Jayaram, R, Jiang, L, et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 374 (2016), 1744–1753.
42. 42 Haissaguerre, M, Jais, P, Shah, DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 (1998), 659–666.
43. 43 Chen, SA, Hsieh, MH, Tai, CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 100 (1999), 1879–1886.
44. 44 Calkins, H, Kuck, KH, Cappato, R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm 9 (2012), 632–696.
45. 45 Calkins, H, Reynolds, MR, Spector, P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2 (2009), 349–361.
46. 46 Piccini, JP, Lopes, RD, Kong, MH, Hasselblad, V, Jackson, K, Al-Khatib, SM, Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2 (2009), 626–633.
47. 47 Wokhlu, A, Monahan, KH, Hodge, DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 55 (2010), 2308–2316.
48. 48 Kirchhof, P, Breithardt, G, Camm, AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 166 (2013), 442–448.
49. 49 Parkash, R, Tang, AS, Sapp, JL, Wells, G, Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 22 (2011), 729–738.
50. 50 Morillo, CA, Verma, A, Connolly, SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 311 (2014), 692–700.
51. 51 Cosedis Nielsen, J, Johannessen, A, Raatikainen, P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 367 (2012), 1587–1595.
52. 52 Stabile, G, Bertaglia, E, Senatore, G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 27 (2006), 216–221.
53. 53 Mont, L, Bisbal, F, Hernandez-Madrid, A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J 35 (2014), 501–507.
54. 54 Krittayaphong, R, Raungrattanaamporn, O, Bhuripanyo, K, et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 86:suppl 1 (2003), S8–16.
55. 55 Wazni, OM, Marrouche, NF, Martin, DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293 (2005), 2634–2640.
56. 56 Oral, H, Pappone, C, Chugh, A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354 (2006), 934–941.
57. 57 Pappone, C, Augello, G, Sala, S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 48 (2006), 2340–2347.
58. 58 Jais, P, Cauchemez, B, Macle, L, et al. Catheter Ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118 (2008), 2498–2505.
59. 59 Forleo, GB, Mantica, M, De Luca, L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 20 (2009), 22–28.
60. 60 Wilber, DJ, Pappone, C, Neuzil, P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303 (2010), 333–340.
61. 61 Packer, DL, Kowal, RC, Wheelan, KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 61 (2013), 1713–1723.
62. 62 Verma, A, Jiang, C-Y, Betts, TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372 (2015), 1812–1822.
63. 63 Kuck, KH, Brugada, J, Furnkranz, A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 374 (2016), 2235–2245.
64. 64 Gaztanaga, L, Frankel, DS, Kohari, M, Kondapalli, L, Zado, ES, Marchlinski, FE, Time to recurrence of atrial fibrillation influences outcome following catheter ablation. Heart Rhythm 10 (2013), 2–9.
65. 65 Deshmukh, A, Patel, NJ, Pant, S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 128 (2013), 2104–2112.
66. 66 Sairaku, A, Yoshida, Y, Nakano, Y, et al. Who is the operator, that is the question: a multicentre study of catheter ablation of atrial fibrillation. Europace, 2016, 10.1093/europace/euv424 published online Feb 2.
67. 67 Weerasooriya, R, Khairy, P, Litalien, J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. J Am Coll Cardiol 57 (2011), 160–166.
68. 68 Ouyang, F, Tilz, R, Chun, J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 122 (2010), 2368–2377.
69. 69 Narayan, SM, Baykaner, T, Clopton, P, et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation). J Am Coll Cardiol 63 (2014), 1761–1768.
70. 70 Barnett, AS, Bahnson, TD, Piccini, JP, Recent advances in lesion formation for catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol, 9, 2016, e003299.
71. 71 Di Biase, L, Gaita, F, Toso, E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 11 (2014), 791–798.
72. 72 Di Biase, L, Burkhardt, JD, Santangeli, P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 129 (2014), 2638–2644.
73. 73 Cappato, R, Marchlinski, FE, Hohnloser, SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 36 (2015), 1805–1811.
74. 74 Chao, TF, Lin, YJ, Tsao, HM, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 58 (2011), 2380–2385.
75. 75 Noseworthy, PA, Yao, X, Deshmukh, AJ, et al. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc, 4, 2015, e002597.
76. 76 Kawasaki, R, Gauri, A, Elmouchi, D, et al. Atrioesophageal fistula complicating cryoballoon pulmonary vein isolation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 25 (2014), 787–792.
77. 77 Cappato, R, Calkins, H, Chen, SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
78. 78 Shah, RU, Freeman, JV, Shilane, D, Wang, PJ, Go, AS, Hlatky, MA, Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 59 (2012), 143–149.
79. 79 Piccini, JP, Sinner, MF, Greiner, MA, et al. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation 126 (2012), 2200–2207.
80. 80 Cummings, JE, Schweikert, RA, Saliba, WI, et al. Brief communication: atrial-esophageal fistulas after radiofrequency ablation. Ann Intern Med 144 (2006), 572–574.
81. 81 Holmes, DR Jr, Monahan, KH, Packer, D, Pulmonary vein stenosis complicating ablation for atrial fibrillation: clinical spectrum and interventional considerations. JACC Cardiovasc Interv 2 (2009), 267–276.
82. 82 Cox, JL, Boineau, JP, Schuessler, RB, et al. Successful surgical treatment of atrial fibrillation. Review and clinical update. JAMA 266 (1991), 1976–1980.
83. 83 Cox, JL, Ad, N, Palazzo, T, Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 118 (1999), 833–840.
84. 84 Themistoclakis, S, Wazni, OM, Saliba, W, et al. Endoscopic fiberoptic assessment of balloon occlusion of the pulmonary vein ostium in humans: comparison with phased-array intracardiac echocardiography. Heart Rhythm 3 (2006), 44–49.
85. 85 Nakagawa, H, Antz, M, Wong, T, et al. Initial experience using a forward directed, high-intensity focused ultrasound balloon catheter for pulmonary vein antrum isolation in patients with atrial fibrillation. J Cardiovasc Electrophysiol 18 (2007), 136–144.
86. 86 Roy, D, Talajic, M, Nattel, S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008), 2667–2677.
87. 87 Dagres, N, Varounis, C, Gaspar, T, et al. Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. J Card Fail 17 (2011), 964–970.
88. 88 Suman-Horduna, I, Roy, D, Frasure-Smith, N, et al. Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 61 (2013), 455–460.
89. 89 Aleong, RG, Sauer, WH, Davis, G, et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta389 arg/gly adrenergic receptor polymorphism. JACC Heart Fail 1 (2013), 338–344.
90. 90 Boriani, G, Savelieva, I, Dan, GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 17 (2015), 1169–1196.
91. 91 Gillis, AM, Mathison, HJ, Kulisz, E, Lester, WM, Dispersion of ventricular repolarization in left ventricular hypertrophy: influence of afterload and dofetilide. J Cardiovasc Electrophysiol 9 (1998), 988–997.
92. 92 Chung, R, Houghtaling, PL, Tchou, M, et al. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. Pacing Clin Electrophysiol 37 (2014), 1338–1348.
93. 93 Crystal, E, Garfinkle, MS, Connolly, SS, Ginger, TT, Sleik, K, Yusuf, SS, Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev, 4, 2004 CD003611.
94. 94 Gillinov, M, Mick, S, Mihaljevic, T, Suri, RM, Watch one, do one, teach one. J Thorac Cardiovasc Surg 151 (2016), 1506–1507.